H1 2026 report
Rdzeń biznesowy (dystrybucja/serwis sprzętu medycznego, głównie da Vinci) rośnie organicznie o 34,6% r/r przy jednoczesnej poprawie marży EBITDA segmentu o 2,0 pkt proc.
Sentiment
Positive
No guidance change
SNT
H1 2026 report
Revenue
441.16 m PLN
— YoY
Net income
331.33 m PLN
— YoY
EBITDA
118.03 m PLN
— YoY
Gross margin
35.33%
— YoY
Summary
Investment thesis
- Rosnący udział przychodów powtarzalnych (+41% r/r w ujęciu 12-miesięcznym) buduje coraz bardziej defensywny profil przychodów
- Raportowany zysk netto (331,3 mln zł) w 79% pochodzi z jednorazowego, niegotówkowego zysku na wydzieleniu Syn2bio S.A. - wynik z działalności kontynuowanej to 82,9 mln zł (+50% r/r)
- Pozycja gotówkowa netto odwróciła się z netto cash do netto długu w ciągu jednego półrocza (dywidenda + finansowanie wydzielenia), ale zadłużenie pozostaje marginalne (dług netto/EBITDA ~0,1x)
- Rosnący backlog (114,3 mln zł, z 10,8 mln zł rok wcześniej) i nowe umowy dystrybucyjne (HistoSonics/Edison) dają widoczność na dalszy wzrost
Read the full analysis
Financial data is open to everyone. The full analysis — management verdict, commentary, risks, and the full narrative — is available after you sign up or log in.
Financials
BETA
SNT · H1 2026
| Metric | H1 2026 | H1 2025 | Δ YoY | YTD 2026 | Δ YoY | Value type | Segment | Conf. |
|---|---|---|---|---|---|---|---|---|
| Revenue | 441.16 | — | — | 441.16 | — | reported | — | 1.00 |
| Gross profit | 155.82 | — | — | 155.82 | — | derived | — | 0.90 |
| EBITDA | 118.03 | — | — | 118.03 | — | reported | — | 0.95 |
| EBIT | 107.69 | — | — | 107.69 | — | reported | — | 1.00 |
| EBT | 102.54 | — | — | 102.54 | — | reported | — | 1.00 |
| Net income | 331.33 | — | — | 331.33 | — | reported | — | 1.00 |
| EPS (basic) | 0 | — | — | 0 | — | reported | — | 1.00 |
| D&A | 10.66 | — | — | 10.66 | — | reported | — | 1.00 |
| Interest expense | 1.19 | — | — | 1.19 | — | reported | — | 0.90 |
| Shares (basic) (m units) | 8.53 | — | — | — | — | reported | — | 1.00 |
| Gross margin | 35.33% | — | — | 35.33% | — | reported | — | 0.90 |
| EBITDA margin | 26.76% | — | — | 26.76% | — | reported | — | 0.90 |
| EBIT margin | 24.41% | — | — | 24.41% | — | reported | — | 0.90 |
| Net margin | 18.79% | — | — | 18.79% | — | reported | — | 0.85 |
| Cash | 36.14 | — | — | — | — | reported | — | 1.00 |
| Total debt | 56.99 | — | — | — | — | reported | — | 1.00 |
| Net debt | 20.85 | — | — | — | — | derived | — | 0.90 |
| Equity | 158.67 | — | — | — | — | reported | — | 1.00 |
| Total assets | 488.24 | — | — | — | — | reported | — | 1.00 |
| Working capital | 59.38 | — | — | 59.38 | — | reported | — | 1.00 |
| Current assets | 319.05 | — | — | — | — | reported | — | 1.00 |
| Current liabilities | 259.67 | — | — | — | — | reported | — | 1.00 |
| Goodwill | 36.75 | — | — | — | — | reported | — | 0.90 |
| CFO | 78.09 | — | — | 78.09 | — | reported | — | 1.00 |
| CapEx | 15.82 | — | — | 15.82 | — | reported | — | 1.00 |
| FCF | 62.27 | — | — | 62.27 | — | derived | — | 0.90 |
| Dividends paid | 91.69 | — | — | 91.69 | — | reported | — | 1.00 |
| Current ratio | 1.23x | — | — | 1.23x | — | reported | — | 0.90 |
| Net debt / EBITDA | 0.1x | — | — | — | — | reported | — | 0.70 |
| Revenue growth (YoY) | 34.58% | — | — | — | — | reported | — | 0.90 |
| EBITDA growth (YoY) | 45.83% | — | — | — | — | reported | — | 0.90 |
| EBIT growth (YoY) | 51.55% | — | — | — | — | reported | — | 0.90 |
| Net income growth (YoY) | 50.23% | — | — | — | — | reported | — | 0.85 |
H1 2026 · Δ YoY
Revenue
441.16
—
441.16
—
- H1 2025
- —
- YTD 2026
- 441.16
- Δ YoY
- —
Gross profit
155.82
—
155.82
—
- H1 2025
- —
- YTD 2026
- 155.82
- Δ YoY
- —
EBITDA
118.03
—
118.03
—
- H1 2025
- —
- YTD 2026
- 118.03
- Δ YoY
- —
EBIT
107.69
—
107.69
—
- H1 2025
- —
- YTD 2026
- 107.69
- Δ YoY
- —
EBT
102.54
—
102.54
—
- H1 2025
- —
- YTD 2026
- 102.54
- Δ YoY
- —
Net income
331.33
—
331.33
—
- H1 2025
- —
- YTD 2026
- 331.33
- Δ YoY
- —
EPS (basic)
0
—
0
—
- H1 2025
- —
- YTD 2026
- 0
- Δ YoY
- —
D&A
10.66
—
10.66
—
- H1 2025
- —
- YTD 2026
- 10.66
- Δ YoY
- —
Interest expense
1.19
—
1.19
—
- H1 2025
- —
- YTD 2026
- 1.19
- Δ YoY
- —
Shares (basic)
(m units)
8.53
—
8.53
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Gross margin
35.33%
—
35.33%
—
- H1 2025
- —
- YTD 2026
- 35.33%
- Δ YoY
- —
EBITDA margin
26.76%
—
26.76%
—
- H1 2025
- —
- YTD 2026
- 26.76%
- Δ YoY
- —
EBIT margin
24.41%
—
24.41%
—
- H1 2025
- —
- YTD 2026
- 24.41%
- Δ YoY
- —
Net margin
18.79%
—
18.79%
—
- H1 2025
- —
- YTD 2026
- 18.79%
- Δ YoY
- —
Cash
36.14
—
36.14
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total debt
56.99
—
56.99
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net debt
20.85
—
20.85
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Equity
158.67
—
158.67
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Total assets
488.24
—
488.24
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Working capital
59.38
—
59.38
—
- H1 2025
- —
- YTD 2026
- 59.38
- Δ YoY
- —
Current assets
319.05
—
319.05
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Current liabilities
259.67
—
259.67
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Goodwill
36.75
—
36.75
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
CFO
78.09
—
78.09
—
- H1 2025
- —
- YTD 2026
- 78.09
- Δ YoY
- —
CapEx
15.82
—
15.82
—
- H1 2025
- —
- YTD 2026
- 15.82
- Δ YoY
- —
FCF
62.27
—
62.27
—
- H1 2025
- —
- YTD 2026
- 62.27
- Δ YoY
- —
Dividends paid
91.69
—
91.69
—
- H1 2025
- —
- YTD 2026
- 91.69
- Δ YoY
- —
Current ratio
1.23x
—
1.23x
—
- H1 2025
- —
- YTD 2026
- 1.23x
- Δ YoY
- —
Net debt / EBITDA
0.1x
—
0.1x
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Revenue growth (YoY)
34.58%
—
34.58%
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
EBITDA growth (YoY)
45.83%
—
45.83%
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
EBIT growth (YoY)
51.55%
—
51.55%
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —
Net income growth (YoY)
50.23%
—
50.23%
—
- H1 2025
- —
- YTD 2026
- —
- Δ YoY
- —